Nanomedicine Meets microRNA: Current Advances in RNA-Based Nanotherapies for Atherosclerosis.
Nanomedicine Meets microRNA: Current Advances in RNA-Based Nanotherapies for Atherosclerosis.
复制标题
DOI：
10.1161/atvbaha.116.307481
复制
发表时间：
2016-09
期刊：
影响因子：
--
通讯作者：
Rayner KJ
中科院分区：
文献类型：
--
作者：
Gadde S;Rayner KJ
心血管疾病几乎占全球所有死亡人数的一半，现在已超过传染病，成为发展中国家死亡和残疾的主要原因。目前，诸如降低低密度脂蛋白的他汀类药物和抗高血压药物等治疗已经开始使冠状动脉疾病(CAD)的死亡率曲线弯曲；然而，随着我们逐渐认识到血管壁中更复杂的病理生理过程，有机会微调治疗方法，使其更直接地针对驱动CAD的机制。已发现的microRNAs可以控制血管细胞的动态平衡、脂蛋白代谢和炎症细胞的功能。尽管这些miRNAs在推动动脉粥样硬化和血管功能障碍方面很重要，但以细胞和上下文特异的方式对miRNAs进行治疗性调节一直是一个挑战。在这篇综述中，我们将总结基于microRNA的治疗方法的出现，作为一种治疗冠心病的方法，特别是针对导致疾病的途径。我们将重点介绍纳米粒子作为一种特定靶向血管壁的手段的最新发展，以及这些纳米药物在治疗冠心病方面的未来。
Cardiovascular disease accounts for almost half of all deaths worldwide, and has now surpassed infectious disease as the leading cause of death and disability in developing countries. At present, therapies such as LDL-lowering statins and anti-hypertensive drugs have begun to bend the morality curve for coronary artery disease (CAD); yet, as we come to appreciate the more complex pathophysiological processes in the vessel wall, there is an opportunity to fine-tune therapies to more directly target mechanisms that drive CAD. MicroRNAs have been identified that control vascular cell homeostasis, lipoprotein metabolism and inflammatory cell function. Despite the importance of these miRNAs in driving atherosclerosis and vascular dysfunction, therapeutic modulation of miRNAs in a cell- and context-specific manner has been a challenge. In this review, we will summarize the emergence of microRNA-based therapies as an approach to treat CAD by specifically targeting the pathways leading to the disease. We will focus on the latest development of nanoparticles as a means to specifically target the vessel wall, and what the future of these nanomedicines may hold for the treatment of CAD.